Skip to Main Content
Upsher-Smith in 2024: Statement on What We’re Committed to, and Capable of, Doing in the New Year

Upsher-Smith Adds Two New Products to its Near-Term Generic Pipeline

Strategic Partnership with CorePharma Further Expands Company’s Portfolio 

Maple Grove, MN – October 19, 2022 — Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has added two near-term generic products to its portfolio in an exclusive agreement with CorePharma, LLC (CorePharma). Under the terms of the agreement, CorePharma will secure FDA approval and manufacture both products at its New Jersey manufacturing facility. Upon FDA approval, Upsher-Smith will market and distribute the products under its own label in the US. 

This collaboration supports Upsher-Smith’s company-wide effort to grow the Company’s portfolio of products through strategic partnerships and product acquisitions. 

“Our partnership with CorePharma, a leader in product development and manufacturing, is especially significant as it provides Upsher-Smith with two near-term product opportunities that will help maximize top-line revenue in FY2022,” said Arun Nataraj, Vice President, Corporate Development, Upsher-Smith. “This is the latest of four recently completed strategic partnerships, reflecting the rapid execution of our external development strategy to expand our generic portfolio.” 

Rich Fisher, President and COO, Upsher-Smith added, “Over the past six months, our corporate development team has had great success expanding our portfolio of high-quality generic products and positioning Upsher-Smith for both near-term and future growth. We look forward to a productive partnership with CorePharma.” 

“CorePharma is extremely happy to partner with a world class organization such as Upsher-Smith,” said Arpit Patel, Chief Executive Officer, CorePharma. “With their strong commercial experience in the US Market, we are confident of the success of these product launches and are looking forward to expanding our partnership across many other future opportunities.” 

Upsher-Smith will open its world-class manufacturing facility in Maple Grove, MN early next year. The new, 270,000 square foot facility will have fully up-to-date serialization and packaging capabilities and has capacity and capabilities that can support contract manufacturing for third parties. To learn more, visit 

About Upsher-Smith 

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to consistent product supply. For more information, visit 

About CorePharma 

CorePharma, founded in 1998, is a “Quality Driven + People Powered” US based CDMO of high-quality branded and generic pharmaceuticals across a broad range of therapeutic areas. The Company’s Middlesex, NJ based headquarters includes three state of the art, USFDA and DEA approved Development, Manufacturing and Packaging facilities totaling 100,000 square feet and a capacity to produce 3 billion dosage units per year. With an excellent regulatory inspection track record, the company is focused on providing partners with an end-to-end, development through commercial launch platform for success. For more information, visit 


Join Our Team!

We’re hiring

Search Our Jobs